Moskal Joseph T, Harris Ryan N, Capps Susan G
Virginia Tech Carilion School of Medicine, Roanoke, VA.
BENSOL, Warsaw, IN.
J Arthroplasty. 2015 Mar;30(3):365-8. doi: 10.1016/j.arth.2014.10.008. Epub 2014 Oct 12.
Tranexamic acid (TXA) has proven to be very advantageous to the total knee arthroplasty (TKA) population. With TXA, the need for allogeneic blood transfusion is reduced and thus hospital costs are reduced. In our hospital system, before TXA was used, facility cost was an estimated $84.90/TKA for blood transfusion and required 0.13 man-hours/TKA (transfusion rate 6.5%); after incorporating intravenous TXA, cost was $82.59/TKA for blood transfusion and TXA medication and 0.007 man-hours/TKA (transfusion rate 0.3%). There were no transfusions when TXA was applied topically, and the facility cost was $39.14/TKA and no employee hours consumed. Topical TXA has the potential to significantly reduce blood transfusions and decrease hospital man-hours/TKA as well as achieve larger cost saving.
氨甲环酸（TXA）已被证明对全膝关节置换术（TKA）患者非常有益。使用TXA后，异体输血的需求减少，从而降低了医院成本。在我们的医院系统中，在使用TXA之前，输血的设备成本估计为每例TKA 84.90美元，每例TKA需要0.13工时（输血率6.5%）；在加入静脉注射TXA后，输血和TXA药物治疗的成本为每例TKA 82.59美元，每例TKA需要0.007工时（输血率0.3%）。局部应用TXA时未进行输血，设备成本为每例TKA 39.14美元，且不消耗员工工时。局部应用TXA有可能显著减少输血，降低每例TKA的医院工时，并实现更大的成本节约。
